Diagnosis and treatment of hepatobiliary and pancreatic disorders of the dog and cat by Squires, Richard A.
  
 
 
Small Animal Medicine, Module 9 
Gastroenterology 1 – The Liver and Pancreas 
 
 
 
 
8th November 2005 
 
 
 
 
 
Richard A. Squires BVSc, PhD, DVR, DipACVIM, DipECVIM-CA, MRCVS 
1 
Diagnosis of hepatobiliary diseases – An  overview 
Underlying pathophysiology 
Webster, CRL. History, Clinical Signs, and Physical Findings 
in Hepatobiliary Disease. In: Ettinger, SJ; Feldman, EC. 
(Eds.) Textbook of Veterinary Internal Medicine, Sixth 
Edition. St Louis, Mo: Elsevier/Saunders, 2005; 1422-1434. 
The liver has many, diverse functions within the body and this is reflected in the many 
consequences of liver dysfunction.  Like the kidneys, the liver has considerable functional reserve, 
so that significant hepatobiliary disease can exist before signs of dysfunction become evident.  
Clinical features of early liver disease are non-specific and include polyuria/polydipsia (PU/PD), 
vomiting, lethargy and inappetence.  Findings that are suggestive of more severe hepatobiliary 
disease include: icterus, hyperammonaemia (leading to hepatic encephalopathy), hypoglycaemia, 
ascites and haemostatic disorders.  Needless to say, there are many other causes of most of these 
clinical findings. 
Pathophysiological ‘explanations’ of some of the possible clinical features of hepatobiliary disease 
are offered in concise form below:- 
• Icterus (jaundice):  decreased uptake, conjugation and/or transport of bilirubin into the 
bile. 
• Microhepatica:  liver fibrosis or inadequate liver perfusion (as seen in portosystemic 
vascular anomalies, PSVAs). 
• Hepatomegaly: infiltration of the liver with glycogen, lipid, amyloid or cells (e.g., 
inflammatory or neoplastic cells); congestion of the liver (right heart failure). 
• Peritoneal effusion: hypoalbuminaemia, portal hypertension, right heart failure, excessive 
renal sodium and water retention, hepatic neoplasia, bile duct or gallbladder rupture. 
• PU/PD: decreased production of urea by the liver, increased production and decreased 
hepatic metabolism of cortisol, primary (psychogenic) polydipsia, hypokalaemia, 
stimulation of thirst due to HE. 
• Pollakiuria/stranguria/dysuria: ammonium biurate urolithiasis (occasionally seen as a 
consequence of portosystemic anomalous vascular shunting). 
• Dullness/lethargy/head pressing/decreased level of mentation:  HE, hypoglycaemia, 
vitamin B1 deficiency. 
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• Vomiting/diarrhoea/melaena/inappetence: gastroduodenal ulceration, steatorrhoea, portal 
hypertension (its effects upon the intestines), stimulation of the vomiting centre/CRTZ. 
Case scenario 
A seven year-old female spayed Doberman pinscher is presented to an 
emergency room in a coma.  The owner reports some depression and 
'vacancy' over the last several weeks. Faeces are black and tarry on rectal 
examination.  PCV and TPP are both moderately low.  There is moderate 
hypoglycaemia.  A buccal mucosal bleeding time is markedly prolonged but 
the activated clotting time is within the normal range. 
Ultimately this dog turns out to be comatose as a consequence of 
advanced chronic hepatitis and gastrointestinal bleeding.  Reflect upon this 
information and generate some plausible pathophysiological explanations 
for the clinical observations.  Why wasn't the chronic active hepatitis 
detected earlier? 
 
Signalment 
Although many of the clinical features of hepatobiliary disease are non-specific, a consideration of 
the age, breed and sex of a patient will sometimes alert the clinician to the possibility that liver 
disease may be present.  This is an example of the use of ‘probabilistic reasoning’.  Below is a list 
of some breed, age and sex associations in liver disease:- 
• Bedlington terrier:  inherited disorder of hepatic copper metabolism leading to marked 
copper accumulation in the liver. 
• West Highland white terrier, Skye terrier, Dalmatian, Siamese cat (plus, perhaps, 
many others): less well-defined copper-associated hepatopathies in which copper 
accumulation is probably not the primary factor. 
• Doberman pinscher (especially middle-aged females), English and American cocker 
spaniels (especially young males), Standard poodle, Labrador retriever: chronic, 
idiopathic hepatitis. 
• Persian and Himalayan cats (often less than two years of age): portosystemic vascular 
anomalies. 
• Yorkshire terrier, Maltese, Dandie Dinmont terrier, Pug, Miniature schnauzer (often 
less than two years of age): extrahepatic portosystemic vascular anomalies. 
• Australian cattle dog, old English sheepdog, Irish wolfhound, Golden and Labrador 
retrievers (often less than two years of age): intrahepatic portosystemic vascular 
anomalies. 
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• Cairn terriers and many of the other breeds prone to PSS:  microvascular dysplasia. 
• Chinese Shar Pei; Abyssinian, Siamese and Oriental cats: hepatic amyloidosis. 
Tobias KM, Rohrbach BW. Association of breed with the 
diagnosis of congenital portosystemic shunts in dogs: 2,400 
cases (1980-2002). J Am Vet Med Assoc. 2003; 223(11):1636-9. 
Hoskins, JD. Liver disease in the geriatric patient. 
Veterinary Clinics of North America. Small Animal Practice 
2005; 35: 617-634. 
History 
In addition to some of the features mentioned above under ‘Pathophysiology’, historical findings 
suggestive of hepatobiliary disease include: 
• Stunted growth; 
• Previous cystotomy for ammonium biurate urolithiasis (suggests PSS); 
• Recent treatment with a potentially hepatotoxic drug; 
• Anaesthetic intolerance; 
• Drug intolerance; 
• Recent, marked weight loss and anorexia in a previously obese cat (often after stress; 
suggests hepatic lipidosis). 
 
Physical Examination 
In addition to some of the features mentioned above, under ‘Pathophysiology’, poor body condition 
score is a physical examination finding found in many, but not all, patients with significant 
hepatobiliary disease.  It is easier to palpate hepatomegaly (especially in cats) than it is to 
appreciate microhepatica.  Discrete liver masses are often quite easily palpated, unless they are 
located dorsally (such as in the caudate lobe). 
Hepatic encephalopathy (HE) arises as a consequence of the liver’s failure to degrade various 
substances that enter the circulation from the intestinal lumen and act as inhibitory 
neurotransmitters.  Usually, HE manifests with non-specific cerebral signs.  The clinician may 
notice the patient showing dullness and ‘staring into space’ during the physical examination.  In 
more severe cases, there may be head pressing, stupor, or even coma. 
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Stewart, CA; Cerhan, J. Hepatic encephalopathy: a dynamic or 
static condition. Metabolic Brain Disease 2005; 20: 193-204. 
A rare dermatological finding in some patients with chronic hepatobiliary disease is termed 
‘hepatocutaneous syndrome’ or superficial, necrolytic dermatitis.  This condition is associated with 
a crusting, ulcerative dermatitis on the face and distal extremities.  It is also observed occasionally 
in dogs with glucagon-secreting pancreatic tumours. 
March PA, Hillier A, Weisbrode SE, Mattoon JS, Johnson SE, 
DiBartola SP, Brofman PJ. Superficial necrolytic dermatitis 
in 11 dogs with a history of phenobarbital administration 
(1995-2002). J Vet Intern Med. 2004 Jan-Feb;18(1):65-74. 
 
Laboratory tests 
Hall EJ, German AJ.  Laboratory evaluation of hepatic 
disease. In: E. Villiers & L. Blackwood (Eds.) BSAVA Manual 
of Canine and Feline Clinical Pathology, Second Edition. Pp. 
184-206.  
Haemogram 
Haemogram (i.e., complete blood count) findings are relatively non-specific and unhelpful in the 
diagnosis of most cases of hepatobiliary disease.  Patients with liver disease may have anaemia.  If 
the anaemia is regenerative, it is most likely to be a consequence of gastrointestinal bleeding.  Non-
regenerative anaemia is more frequently encountered in patients with hepatobiliary disease and is 
usually normocytic and normochromic.  In most cases it is thought to be a manifestation of 
inflammation and iron sequestration, in other words ‘anaemia of inflammation’ (what used to be 
called ‘anaemia of chronic disease’ or ‘anaemia of chronic inflammation’).  Sometimes microcytic, 
hypochromic, non-regenerative anaemia is present.  This may be a consequence of chronic 
gastrointestinal blood loss and iron deficiency.  Alternatively, when observed in patients with 
portosystemic vascular anomalies, it may be a consequence of defective iron transportation.  Target 
cells and variably shaped cells (poikilocytes) are sometimes seen in animals with liver disease.  
These changes are thought to be a consequence of abnormalities in red blood cell plasma membrane 
lipoproteins. 
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Serum Biochemistry 
Liver enzymes 
Serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline 
phosphatase (ALP) and gamma-glutamyl transpeptidase (γ-GT) are evaluated routinely when 
screening for the presence of hepatobiliary disease in dogs and cats.  Increased activities are 
sensitive indicators of the presence of hepatobiliary disease but have poor specificity.  Diseases 
outside of the liver and administration of various drugs can lead to elevations in the serum activities 
of these enzymes. 
The magnitude of elevation of ALT and AST correlates reasonably well with the extent of recent 
damage but does not provide information about functional reserve or prognosis.  Indeed, animals 
that have lost a great deal of liver tissue to fibrosis may have lower enzyme activities than other 
animals with much greater reserves of liver tissue and a better prognosis. 
ALT 
Serum ALT elevation is a sensitive indicator of hepatocellular damage (or ‘leakage’) in dogs and 
cats.  Acute hepatocellular necrosis causes the highest elevations. It is relatively liver-specific, 
although serum activity may be increased when there is severe muscle disease.  It may also increase 
in situations where the liver is injured or ‘responds’ to systemic or other extra-hepatic disorders (so-
called ‘reactive’ hepatopathies, for example feline hyperthyroidism).  The serum half life of ALT is 
reportedly several hours to several days and much shorter in cats than in dogs.  Therefore small 
ALT increases are more significant in cats than in dogs (although still not indicative of primary 
hepatopathy). 
Although ALT is classically considered a hepatocellular necrosis, ‘leakage’ enzyme, it also 
increases (more slowly) in cholestatic disorders.  The accumulation of toxic bile salts that 
accompanies cholestasis damages hepatocytes and causes enzyme leakage.  ALT elevations seen in 
association with hepatic neoplasia may be a reflection of leakage from abnormal tumour cells or 
tumour-related pressure necrosis. 
It is well-known that several drugs can increase serum activities of ALP by enzyme induction, but 
less widely appreciated that this also seems to happen for ALT.  In dogs, phenobarbital and 
glucocorticoids seem to induce ALT expression.  However, the increases are not dramatic unless 
high, toxic doses of these drugs are used, or an idiosyncratic reaction develops.  Potentially 
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hepatotoxic drugs reported to be able–in some patients–to cause elevation of serum ALT activity 
include griseofulvin, ketoconazole, sulphonamides, azathioprine, paracetamol, phenobarbital, 
halothane and many others. 
Examples of ‘secondary’ causes of ALT elevation, in which primary hepatic disease is not present 
include: 
• Primary gastrointestinal disease (intestinal permeability increases, allowing more ‘toxins’ to 
reach the liver and cause hepatocyte damage; 
• Hyperthyroidism; 
• Fatty infiltration of the liver secondary to a variety of endocrine and metabolic disorders; 
• Liver tissue hypoxia secondary to anaemia; 
• Systemic inflammation; and even 
• Severe periodontal disease. 
 
AST 
This is another ‘leakage’ enzyme that, as well as being found in liver, is also found in substantial 
amounts in the cardiac and skeletal muscles.  It is therefore less specific than ALT as a measure of 
hepatocellular damage.  It seems to have few advantages over ALT, although some authors suggest 
it is a more sensitive indicator of hepatobiliary disease and a more specific marker of severe 
disease.  If the AST level is disproportionately high compared with the ALT, muscle disease should 
be suspected. 
Arginase 
This is yet another marker of hepatocellular injury that is less prone than ALT and AST to 
elevations in ‘secondary’ hepatopathies.  Levels of arginase decline to normal during recovery after 
injury.  Persistent elevations, therefore, may have greater negative prognostic significance than do 
persistent elevations of ALT or AST. 
ALP 
Alternative abbreviations for alkaline phosphatase (ALP) include AP and SAP.  ALP is a 
membrane-bound liver enzyme found on hepatocyte canalicular membranes and on the luminal 
surfaces of the cells lining bile canaliculi.  It is released into the blood during cholestasis as a result 
of hepatocyte damage as well as increased synthesis. Elevation of serum ALP is a sensitive 
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indicator of cholestatic hepatobiliary disease but unfortunately this finding is quite non-specific, 
particularly in dogs.  There are several isoenzymes of ALP produced in the liver, kidneys, bone, 
intestines and placenta. The most important ones that contribute to serum ALP activity in normal, 
healthy animals are the bone and liver isoenzymes. The others have short half-lives and do not 
contribute very much.  One exception is that, in pregnant queens near full-term, the placental 
isoenzyme is a significant contributor to overall serum activity. 
Glucocorticoids (including those administered topically to the eye, ear and skin) and anticonvulsant 
drugs such as phenobarbital induce the synthesis of a second, liver-derived isoenzyme in dogs.  
Glucocorticoids are particularly effective in this regard, so this drug-induced isoenzyme is often 
called ‘corticosteroid-induced’ or ‘steroid-induced’.  Cats do not produce this second, drug-
inducible ALP isoenzyme in response to drug treatment.  Another important difference exists 
between dogs and cats that means that mild-to-moderate elevations of serum ALP in cats are much 
more significant than in dogs. It concerns differences in the half lives of ALP in the two species.  In 
dogs, the half life of both of the liver-derived forms of ALP is approximately 70 hours.  In cats, the 
half life of the single liver-derived isoenzyme is only six hours.  Consequently, an elevation of ALP 
to ~ 200U/L or more is far more significant in a cat than it would be in a dog. 
The different isoenzymes of ALP can be distinguished using laboratory tests (one useful method 
involves the use of levamisole as a reagent).  From the foregoing, it would be tempting to believe 
that it would be diagnostically useful in many clinical situations to quantitate the serum activities of 
the different ALP isoenzymes. However, this has not proved to be the case.  One reason is that 
chronic, stressful illnesses (including hepatobiliary diseases) are thought to be able to lead to 
endogenous glucocorticoid production and induction of the drug-inducible isoenzyme.  In many 
animals with liver disease the total serum ALP activity is comprised of a mixture of drug-inducible 
isoenzyme and liver isoenzyme. 
γ-GT 
γ-GT is another marker of cholestatic or biliary disease and another membrane-bound enzyme 
found in the biliary tree.  Serum activity is mostly derived from the liver, although γ-GT is present 
in many other tissues.  (It is also present at high concentrations in colostrum and milk so that serum 
γ-GT levels can be used in neonatal production animals as a way of judging whether sufficient 
colostrum has been ingested).  Increases in serum activity of γ-GT in patients with cholestasis arise 
as a consequence of elution of the enzyme from hepatocytes and de novo synthesis. 
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γ-GT is not as widely used for diagnostic purposes by clinicians as is ALP.  However, it does have 
some advantages. Since it is not so prone to drug induction, it is more specific (although less 
sensitive) for the detection of liver disease in dogs.  In cats, γ-GT may be a more sensitive indicator 
of cholestasis than is ALP.  One exception is feline hepatic lipidosis which tends to cause ALP 
elevation without γ-GT elevation.  When ALP and γ-GT are used in combination for the detection 
of hepatobiliary disease, high specificity can be achieved. 
Case scenario 
An apparently healthy 14 year-old Beagle is presented for an annual health 
check. Physical examination reveals no significant abnormalities.  Routine 
blood work and UA reveals an ALT of 312 U/L (ref. 8-60) but no other 
abnormalities.  What would be your approach? 
 
Some extrahepatic causes of serum liver enzyme elevation 
Cause ALT AST ALP γ-GT 
Glucocorticoid overexposure + + +++ +/++ 
Anticonvulsant therapy + + +/++ + 
Feline hyperthyroidism +  +  
Canine hypothyroidism   +  
Diabetes mellitus   +  
Muscle damage + ++   
Young growing animal   ++  
Late pregnancy (queen)   +/++  
Severe anaemia / hypoxaemia ++ + -/+ -/+ 
 
Albumin / Globulin 
Albumin is synthesized in the liver so hypoalbuminaemia can be a manifestation of liver failure.  
However, the liver has considerable reserve capacity for albumin synthesis.  Therefore 
hypoalbuminaemia is a manifestation of severe, usually chronic liver disease.  It is most often seen 
in patients with portosystemic vascular anomalies or end-stage, chronic liver disease (often 
associated with cirrhosis).  Hypoalbuminaemia associated with severe liver disease may arise as a 
consequence of failure of hepatic synthesis, but can also be seen because of avid renal sodium and 
water retention or loss of albumin into a ‘third space’ body compartment such as a peritoneal 
effusion.  Hypoalbuminaemia is certainly not a specific sign of liver disease.  It can also be caused 
by protein-losing nephropathies and enteropathies, vasculitis, acute blood loss, cutaneous exudative 
lesions and systemic inflammatory processes. (Serum albumin is a negative acute-phase reactant, 
decreasing in a variety of inflammatory disorders, in parallel with increasing serum globulin).  
Concurrent evaluation of serum globulin concentration in hypoalbuminaemic patients may help to 
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limit the list of differential diagnoses.  For example, protein-losing nephropathies typically cause 
selective hypoalbuminaemia whereas protein-losing enteropathies typically cause 
panhypoproteinaemia.  In severe liver disease, hypoalbuminaemia may be associated with a high, 
normal or (uncommonly) low serum globulin concentration. 
Many non-immunoglobulin globulins are synthesized in liver, so liver failure can lead to 
hypoglobulinaemia.  However, in many hepatic disorders there is an increase in total serum 
globulin concentration, often as a consequence of both immunoglobulin and non-immunoglobulin 
contributions.  Often, hyperglobulinaemia reflects inflammatory processes going on in the liver and 
elsewhere in the body.  The diseased liver may not be able to filter portal blood properly, so that a 
degree of systemic inflammation can be a feature of many serious liver diseases.  
Hyperglobulinaemia is a regular feature of feline infectious peritonitis (FIP), the disease that often 
affects the liver. 
Cholesterol 
Serum cholesterol concentrations are frequently abnormal in patients with significant hepatobiliary 
disease, but measurement of serum cholesterol provides little specific information.  Post-hepatic 
bile duct obstruction (usually expressed as Extrahepatic bile duct obstruction, EHBDO) is usually 
associated with an increase in serum cholesterol.  Conversely, dogs and cats with portosystemic 
vascular anomalies (PSVA), and those with severe, end-stage liver disease, often have low serum 
cholesterol (about 2/3 of dogs and cats with PSVA are hypocholesterolaemic).  
Hypocholesterolaemia may be a consequence of decreased hepatic synthesis or increased 
incorporation into bile acids. 
Glucose 
The liver plays a central role in carbohydrate metabolism and, through glycogen storage and 
gluconeogenesis, serves to prevent fasting hypoglycaemia.  As was the case for albumin synthesis, 
the liver has considerable reserve capacity for glucose production.  Therefore, it is only in patients 
with liver failure (e.g., PSVA or end-stage, chronic disease) that failure to synthesize sufficient 
glucose occurs.  About one-third of dogs with PSVA are intermittently hypoglycaemic. 
Another cause of hypoglycaemia that is occasionally encountered is hepatic neoplasia.  Large 
primary liver tumours, more often encountered in dogs than cats, are frequently associated with 
severe hypoglycaemia, sufficient to cause clinical signs.  If the tumour is difficult to palpate, an 
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initial, incorrect diagnosis of insulinoma may be made.  However, abdominal imaging usually 
resolves the dilemma without difficulty.  These large liver tumours are thought to produce 
hypoglycaemia by consuming glucose or—more likely, considering the severity and persistence of 
the hypoglycaemia despite i.v. glucose infusion—by producing insulin-like growth factors that 
inhibit gluconeogenesis and promote glycogenolysis. 
Rarely, a clinician may encounter a glycogen storage disease (or glycogenosis) causing 
hepatomegaly and hypoglycaemia. 
http://www.shilohgtf.com/Glycogen%20Storage%20Disease.htm  
 
Urea 
Urea is synthesized by the liver, so liver failure may be accompanied by a low serum urea 
concentration.  This is most likely to be observed in patients with PSVA, occurring in 
approximately 2/3 of affected dogs and cats.  A decreased serum urea is certainly not specific for 
liver disease.  Low protein food, fasting, anorexia, intravenous fluid therapy and other causes of 
high renal tubular flow rates (via renal medullary washout) can all cause a relatively low serum urea 
concentration.  Conversely, high protein food, gastrointestinal bleeding, dehydration and renal 
failure can all lead to serum urea elevation.  Since severe liver disease can sometimes lead to 
gastrointestinal bleeding, it is possible for a patient with primary liver disease to have a high, rather 
than low, serum urea concentration. 
Bilirubin 
Bilirubin, a yellow-brown pigment, is a product of haemoglobin metabolism by the mononuclear 
phagocyte system (MPS).  MPS cells are responsible for removing senescent red blood cells from 
the circulation and degrading them.  Haemoglobin from senescent red blood cells is metabolized by 
MPS cells to bilirubin and then released.  The bilirubin released by MPS cells is insoluble in plasma 
and reversibly bound to albumin.  It is taken up by hepatocytes and conjugated with glucuronic 
acid, which renders it soluble in aqueous solution.  This conjugated bilirubin is secreted by 
hepatocytes into the bile, against a concentration gradient.  In the intestine, bilirubin is metabolized 
to colourless urobilinogen and then to brown-pigmented stercobilins. Some of the urobilinogen 
undergoes enterohepatic cycling and some is filtered by the glomeruli and appears in the urine. 
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If hyperbilirubinaemia develops and is sufficiently severe and long-lasting, clinically apparent 
jaundice (icterus) will develop.  Icterus is partly due to staining of connective tissues.  It is most 
readily detected in the sclerae and, particularly in cats, in the soft palate.  When severe, it can be 
striking in the gums.  Some, but not all, forms of liver disease are associated with icterus. For 
example, PSVA, glucocorticoid-induced hepatopathy, and metastatic hepatic neoplasia are rarely, if 
ever, associated with jaundice. 
Hyperbilirubinaemia may be pre-hepatic, hepatic or post hepatic.  Pre-hepatic hyperbilirubinaemia 
is due to excessive extravascular haemolysis, for example as a consequence of immune-mediated 
haemolytic anaemia.  The amount of haemolysis taking place must be sufficiently extreme to 
exceed the considerable capacity of the liver to conjugate and secrete bilirubin into the bile.  
Patients with pre-hepatic hyperbilirubinaemia are invariably anaemic, and usually have severe or 
moderately severe anaemia.  The anaemia, by causing poor oxygen delivery to hepatic tissues, may 
contribute to the inability of the liver to conjugate and secrete sufficient bilirubin in patients with 
pre-hepatic hyperbilirubinaemia. 
Hepatic hyperbilirubinaemia is a consequence of impaired uptake, conjugation or secretion of 
bilirubin into the bile.  Disorders that have severe intrahepatic cholestasis as a feature may be 
accompanied by hepatic hyperbilirubinaemia.  An unusual form of hepatic hyperbilirubinaemia is 
‘cholestasis of inflammation’ or ‘cholestasis of sepsis’.  In this condition, circulating inflammatory 
cytokines prevent hepatocytes from transporting bilirubin into the bile.  The hepatocytes are 
temporarily ‘paralysed’ by the inflammatory process.  Cholestasis of inflammation need not be 
associated with liver enzyme elevations whereas most other forms of hepatic hyperbilirubinaemia 
are. 
Post hepatic hyperbilirubinaemia is a consequence of post hepatic bile duct obstruction or 
discontinuity (e.g., traumatic rupture).  Bile duct tumours, choleliths, biliary sludge, inspissated pus 
and external pressure from (for example) pancreatitis or tumours can all cause bile duct obstruction. 
It is not usually difficult to distinguish pre-hepatic hyperbilirubinaemia from the other forms.  
However, it can be difficult to distinguish hepatic hyperbilirubinaemia from the post hepatic form. 
The most reliable way to distinguish causes of hepatic hyperbilirubinaemia from those causing post 
hepatic hyperbilirubinaemia is to use abdominal imaging, in particular abdominal ultrasonography.  
Dilated, tortuous bile ducts and distension of the gallbladder with loss of tapering of the neck of the 
gallbladder are features of post hepatic bile duct obstruction. Post hepatic hyperbilirubinaemia is 
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more consistently associated with hypercholesterolaemia than is hepatic hyperbilirubinaemia.  
However, this is not a reliable way of making the distinction. 
The so-called Hijmans van den Bergh’s test has been used in the past to distinguish conjugated 
from unconjugated bilirubin and measure their relative proportions.  This test has little diagnostic 
value for reasons that are reminiscent of those previously described for the various isoenzymes of 
ALP.  One might predict that the circulating bilirubin in patients with pre-hepatic 
hyperbilirubinaemia would mostly be unconjugated whereas, in patients with post hepatic 
hyperbilirubinaemia, most would be conjugated.  In reality, conjugated and unconjugated forms of 
bilirubin are found in variable proportions in pre-hepatic, hepatic and post hepatic disorders and 
making the distinction is not usually helpful.  Another important complicating factor that 
diminishes the value of the van den Bergh’s test is the presence of variable amounts of bilirubin 
irreversibly bound to albumin (so-called biliproteins or delta-bilirubin) in some 
hyperbilirubinaemic patients.  This delta-bilirubin, which is measured as direct-reacting, conjugated 
bilirubin in the van den Bergh’s test, persists much longer in the body than do the conventional 
conjugated and unconjugated forms.  Indeed, its half life approximates that of albumin.  Thus, 
hyperbilirubinaemia may persist in some patients long after the underlying disease (e.g. 
pancreatitis) has resolved. 
Urine analysis 
Many patients with hepatobiliary disease have PU/PD and therefore a low urine specific gravity. 
Some dogs and fewer cats with PSVA have detectable ammonium biurate crystalluria on urine 
sediment examination.  This is a consequence of concurrent hyperuricaemia and 
hyperammonaemia.  It may be necessary to examine several fresh urine samples in order to detect 
this crystalluria. 
It is abnormal for cats to have any bilirubin in their urine because they have a high threshold for its 
renal excretion. Therefore, any bilirubin in the urine of a cat qualifies as hyperbilirubinuria and is 
indicative of excessive extravascular haemolysis or hepatobiliary disease.  Conversely, it is normal 
for some dogs (particularly male dogs) to have some conjugated bilirubin in their urine.  If a large 
amount is present (i.e. a strong dipstick reaction), this hyperbilirubinuria has the same significance 
as discovering any bilirubin in the urine of a cat. 
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Urobilinogen is a normal finding in the urine of healthy dogs and cats, although it is not invariably 
detected. An increased amount may be present in the urine of patients with hyperbilirubinaemia.  
Urobilinogen will be absent from the urine of animals that have pale, ‘acholic’ faeces as a 
consequence of complete post hepatic bile duct obstruction. 
Serum bile acids 
Bile acids are synthesized by hepatocytes, secreted into the bile and stored in the gallbladder. After 
a meal is ingested, bile is secreted into the intestinal lumen where bile acids aid in the 
emulsification of dietary fat.  Under normal circumstances, >95% of bile acid molecules are 
reabsorbed from the gut and efficiently extracted from the portal blood by the liver.  This highly 
efficient enterohepatic circulation means that individual bile acid molecules may recycle between 
liver and intestine many times per day.  After digestion of a meal is completed, bile acids are 
efficiently removed from portal blood and stored in the gallbladder. In patients with PSVA, the 
enterohepatic circulation is disturbed and SBAs may be markedly elevated, particularly, post-
prandial values. 
The quantification of pre- and post-prandial serum bile acids (SBAs) for assessment of 
hepatobiliary function is, by now, quite well-established in small animal practice.  Despite this, 
many questions and uncertainties remain in the minds of clinicians about SBA measurements.  The 
following list of key points is not intended to provide an exhaustive coverage of this large and 
complicated topic. It is intended to be read in conjunction with a suitable textbook chapter, for 
example this one:- 
Hall EJ, German AJ.  Laboratory evaluation of hepatic 
disease. In: E. Villiers & L. Blackwood (Eds.) BSAVA Manual 
of Canine and Feline Clinical Pathology, Second Edition. Pp. 
184-206. 
 
• It is not usually helpful to measure SBAs in patients that are already icteric as a 
consequence of hepatic disease.  Measurement of SBAs can be thought of as a rather 
‘subtle’ diagnostic test that is superfluous when something obvious like icterus is already 
present. 
• Measurement of total SBAs, as currently practiced, does not provide specific information 
about particular causes of hepatopathy.  Although SBA quantitation is often used for 
diagnosis of PSVA, it is not a specific test for this purpose. 
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• The severity of disease does not correlate well with the magnitude of elevation of SBAs.  
SBA values should only be interpreted as ‘normal’ or ‘abnormal’. 
• There is some debate about what should be appropriate cut-off values (i.e. upper limit of 
normal) for use when measuring SBAs in dogs and cats.  Some authors recommend cut-off 
values that are much higher than the original ones that were published. Obviously, the 
higher the cut-off value, the greater the specificity but the lower the sensitivity of this 
diagnostic test. 
• There is some debate about the relative merits of measuring pre- and post-prandial SBAs.  
Some authors question whether it is necessary to feed a meal and measure both.  You could 
consult your favourite small animal internal medicine specialist or clinical pathologist to 
devise a protocol for your practice. 
• The effects of haemolysis and lipaemia are important and potentially confusing.  If too large 
a meal is fed to the patient undergoing investigation, it may become lipaemic.  Lipaemia, in 
turn, may cause some haemolysis.  Lipaemia and haemolysis can interfere with the 
measurement of SBAs.  The extent of any haemolysis that may be induced by lipaemia is 
very difficult, or impossible, to predict.  For this reason, it is important to standardize and 
limit the amount of food given to stimulate cholecystokinin release.  Some authors 
recommend 2 tsp of a defined food (for example, Hills canned d/d) be fed to dogs < 5 kg 
and 2 tbsp of the same food defective dogs over 10 kg. Unfortunately, for some dogs, this 
amount of food may be insufficient to stimulate gallbladder emptying.  Consider devising a 
suitable test protocol in collaboration with your favourite clinical pathologist and/or small 
animal internal medicine specialist. 
• In Australia, many Maltese dogs have apparently elevated post-prandial total SBA 
concentrations in the absence of detectable hepatobiliary disease and with normal ammonia 
tolerance. SBAs were measured using a conventional enzymatic spectrophotometric method.  
When high-performance liquid chromatography was used instead for SBA quantitation, 
lower values were obtained, suggesting the presence of interfering substance(s) 
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serum bile acid concentrations and ammonia tolerance in 
Maltese dogs with and without hepatic vascular anomalies.  
Aust Vet J. 1995 Apr;72(4):121-6. 
• Despite these several concerns, measurement of SBAs remains useful, particularly in the 
diagnosis of PSVA.  In the future, measurement of specific acids, rather than total SBAs, may 
prove to be worthwhile and feasible.  Measurement of urinary, rather than serum, bile acids has 
been investigated but has not so far been used widely. 
Blood ammonia 
Normally, ammonia produced by intestinal bacteria is transported in the portal blood to the liver 
where it is converted to urea.  Animals with PSVA or sufficiently severe parenchymal liver disease 
may have abnormally high blood ammonia concentrations.  Although 80-90% of animals with 
PSVA and 50% of animals with parenchymal liver disease have high fasting blood ammonia 
concentrations, use of an ammonia tolerance test (ATT) can increase sensitivity.  In a conventional 
ATT, a 20mg/ml ammonium chloride solution is administered by stomach tube at a dose of 
100 mg/kg (up to a maximum of 3g).  This is done after a 12 hour fast and after a baseline blood 
sample has been taken.  30 minutes later, another blood samples taken and both are submitted for 
ammonia quantitation.  This conventional oral ATT may cause vomiting and can worsen 
encephalopathy.  It is not without risk.  As a modification, a rectal ATT has been devised.  A warm 
water enema is used to empty the rectum 12 hours before the test. After a baseline blood samples 
obtained, ammonium chloride solution (50mg/ml) is administered into the rectum, via catheter, at 
2 ml/kg body weight.  Blood samples are taken a 20 and 40 minutes afterwards.  This test is safer, 
more convenient, less prone to cause vomiting but less sensitive than the oral test.  Finally, a 
modified oral ATT has been described in which food, rather than ammonium chloride solution is 
used.  This test is safe and has good sensitivity for the detection of PSVA but poor sensitivity for 
detection of parenchymal hepatocellular diseases. 
A major limitation of all of these tests that require measurement of blood ammonia is that samples 
need to be handled very carefully.  Blood needs to be drawn into cold heparinized tubes, held on ice 
and transferred promptly to the laboratory.  Dry chemistry methods for detection of ammonia in 
veterinary practice have, unfortunately, been reported to produce unreliable results. 
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Coagulation profile 
All coagulation factors, except Factor VIII, are synthesized by the liver. The vitamin K-dependent 
activation of factors II, VII, IX and X also takes place there.  The liver synthesizes various 
fibrinolytic proteins and some important inhibitors of coagulation and fibrinolysis.  Patients with 
liver disease may have mild thrombocytopenia and/or platelet dysfunction.  It is therefore difficult 
to predict precisely what haemostatic consequences severe liver disease may have in a particular 
patient. 
Vitamin K deficiency may arise in hepatobiliary disease because of failure to absorb this fat-soluble 
vitamin, or failure to store it adequately in the liver. Inadequate dietary intake is a less common 
cause. Relative or absolute vitamin K deficiency will first cause prolongation of the prothrombin 
time (PT) and later cause prolongation of the activated partial thromboplastin time (APTT).  
Another test for detection of vitamin K deficiency involves the detection of circulating, inactive 
forms of the vitamin K-dependent coagulation factors.  These inactive factors are termed proteins 
induced by vitamin K absence or antagonism (PIVKA).  Some authors suggest that measurement of 
PIVKAs may increase the sensitivity with which we can detect animals with hepatobiliary disease 
that are likely to bleed at the time of biopsy.  However, others are unconvinced of the value of 
PIVKA quantitation. 
For safety’s sake, it is certainly recommended to carry out buccal mucosal bleeding time (to assess 
primary haemostasis) and a coagulation screen (e.g. PT, APTT, platelet count ± FDPs) on patients 
immediately prior to hepatic biopsy.  Given that vitamin K deficiency is relatively common in 
animals with severe hepatobiliary disease, some clinicians routinely inject a dose of vitamin K1 
(e.g., 2.5 mg/kg SC) 24 hours before carrying out a final coagulation screen and, all being well, 
carrying out biopsy. Unfortunately, bleeding may still occasionally occur despite normal 
coagulation values and vitamin K pre-treatment.  Fresh frozen plasma should therefore be available 
on hand. 
Imaging 
Radiography 
Plain radiography is excellent for assessing liver size, shape and radio-opacity.  Normally, the liver 
is a homogeneous soft tissue structure present in the cranial abdomen, immediately behind the 
diaphragm.  The stomach is normally immediately behind the liver and, in average-shaped dogs, the 
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gastric axis is approximately parallel with that of the overlying ribs.  The axis is more vertical in 
deep-chested dogs. Usually there is enough gas in the stomach to allow its axis to be assessed. 
Diffuse hepatomegaly is associated with caudal displacement of the stomach and some caudodorsal 
displacement of the pylorus, so that the gastric axis becomes closer to horizontal.  The caudal 
ventral margin of the enlarged liver (in the lateral projection) sometimes appears obviously 
rounded.  Sometimes the shadow of the liver and the spleen merge in the lateral projection, so that it 
is wise to speak of ‘hepatosplenomegaly’ rather than, over-confidently assuming the enlargement is 
definitely liver. 
Microhepatica is seen in patients with PSVA and severe, often end-stage liver fibrosis.  The liver 
shadow may literally be a thin ‘sliver’ in the cranial abdomen.  The pylorus of the stomach is 
displaced cranially and ventrally compared with normal, so that the stomach may be are orientated 
vertically, or even have the pylorus positioned cranial to the fundus in the lateral projection. 
Gallstones (choleliths) and other calcifications and concretions within the biliary tree may appear as 
radiopaque structures superimposed on the liver shadow.  Choleliths are usually seen as discrete, 
round, mineralized structures in the cranial, right, ventral liver.  Other changes in radio-opacity that 
may be observed include diffuse hepatic mineralization and focal areas of mineralization (due to 
infection, granuloma formation, neoplasia, or resolving abscesses or haematomas). 
PSVA can be diagnosed by contrast imaging of the portal venous system.  The best method is 
termed ‘operative mesenteric portography’ and involves general anaesthesia, laparotomy and 
catheterization of a mesenteric jejunal vein.  An aqueous iodinated contrast agent is rapidly injected 
and (preferably) several radiographs are made rapidly afterwards.  Alternatively, fluoroscopy can be 
used. 
Ultrasonography 
Abdominal ultrasonography can be extremely useful in the investigation of hepatobiliary disorders.  
For example, it may be crucial in enabling the clinician to distinguish intrahepatic from post hepatic 
disease.  It can be used to assess focal, multinodular or diffuse disease, so is often used to guide 
clinicians when taking liver biopsies. 
Complete post hepatic biliary obstruction is associated with dilatation and tortuousity of bile ducts. 
The changes become more obvious and extensive as time passes after the obstruction. 
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Normal liver tissue appears homogeneous under ultrasound examination.  The echogenicity of 
normal liver parenchyma is approximately the same as that of renal cortex.  Hypoechoic tubular 
structures should be visible within the parenchyma; these represent hepatic and portal veins. 
Disease processes that typically cause a diffuse increase in hepatic parenchymal echogenicity 
include: fibrosis, lipidosis, steroid hepatopathy, and various forms of neoplasia.  Fibrotic livers will 
typically be smaller than normal whereas, in steroid hepatopathy, the liver may be normal-sized or 
large.  Having said that, ultrasonography is not as reliable as radiography for determining liver size. 
Disease processes that typically cause a diffuse decrease in hepatic parenchymal echogenicity 
include: suppurative inflammation, passive congestion and some forms of hepatic lymphoma. 
Haematomas and abscesses have variable appearance depending upon their maturity.  Both tend to 
begin as hyperechoic structures and mature to become hypoechoic and more clearly marginated. 
Primary liver tumours are usually large, solitary and relatively well circumscribed.  They typically 
distort and protrude beyond the normal liver outline.  Hepatic lymphoma may appear as diffuse 
hyper- or hypoechogenicity of the liver parenchyma or as multiple ‘targetoid lesions’, in each of 
which there is a central area of hyperechogenicity surrounded by a ring of hypoechogenicity. 
In expert hands, abdominal ultrasonography is an accurate way of detecting PSVAs.  The liver is 
usually small with less prominent than normal vascular structures.  The kidneys may be large and 
bladder calculi may be observed (ammonium biurate uroliths).  In extrahepatic PSVAs, the 
abnormal shunting vessel may be directly visualized.  This is more easily done if Doppler 
ultrasound is available, since high velocity turbulent flow may be observed in the abnormal, 
shunting vessel.  The hepatic portal vein, if visualized, may be smaller than usual. Intrahepatic 
PSVAs can also be detected relatively easily by experts. 
Scintigraphy 
Per-rectal scintigraphy is used in dogs and cats for the detection of PSVAs.  A small amount of 
radioactive 99mtechnetium pertechnetate is administered via catheter to the animal’s rectum.  The 
animal is positioned over a gamma camera while this is done.  From the rectum, the radioactive dye 
is absorbed rapidly and, in normal animals, appears first in the liver and then in the heart and lungs.  
In animals with portosystemic shunting, radioactivity is detected in the heart and lungs before or at 
the same time as it is first detected in the liver.  Rectal scintigraphy does not distinguish congenital 
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from acquired shunts.  Animals with microvascular dysplasia or parenchymal liver diseases without 
acquired shunts have normal scans. 
Liver biopsy 
The crucial importance of taking precautions to minimize the risk of haemorrhage when obtaining 
liver biopsies has already been emphasized. 
Fine needle aspiration (FNA) of the liver and cytological examination of aspirates will occasionally 
provide diagnostically useful information (for example, it may yield a specific diagnosis of hepatic 
carcinoma or lymphoma).  Unfortunately FNA agrees with ‘proper’ hepatic biopsy only in a 
minority of instances.  In fact, it may yield partial information that misleads the clinician.  For 
example, vacuolar hepatopathy (e.g., due to hepatic lipidosis in a cat or steroid hepatopathy in a 
dog) may be the only finding on FNA when a full biopsy would have revealed further changes (e.g.,  
necrosis, active inflammation, infection; perhaps an underlying cause for the vacuolar changes).  
Nevertheless, there are some situations in which FNA is the only diagnostic option available to the 
clinician.  It may be possible to increase the accuracy of FNA somewhat by taking several aspirates. 
Wang KY, Panciera DL, Al-Rukibat RK, Radi ZA.  Accuracy of 
ultrasound-guided fine-needle aspiration of the liver and 
cytologic findings in dogs and cats: 97 cases (1990-2000). J 
Am Vet Med Assoc. 2004 Jan 1;224(1):75-8. 
Ultrasound-guided needle biopsies or wedge biopsies obtained at laparotomy are the kinds most 
commonly evaluated.  Some practices are equipped to obtain biopsies at laparoscopy.  
Unfortunately, tiny needle biopsies obtained under ultrasound guidance do not provide results that 
correlate particularly well with those provided by much larger wedge biopsies.  It is therefore 
particularly important, when taking or requesting ultrasound-guided needle biopsies, to obtain 
adequate tissue. Three pieces of liver tissue that more-or-less fill the cavity in a 16G or larger 
biopsy needle are needed.  The use of 14G biopsy needles may increase diagnostic accuracy, but 
also increase the risk of haemorrhage. Alternatively, if laparoscopy is unavailable, a wedge biopsy 
can be obtained at laparotomy.  Although this is more invasive and expensive, it allows collection 
of a larger amount of tissue and proper attention to haemostasis. 
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and wedge biopsy specimens of the liver in dogs and cats. 
Journal of the American Veterinary Medical Association 2002; 
220: 1483-1490. 
If an adequate biopsy is submitted for histopathological examination by an expert, it should be 
possible to establish the following: 
• the category of disease process that is present (e.g., neoplastic, vascular, vacuolar); 
• the degree of severity of that disease process (e.g., mild, moderate or severe); 
• the degree of chronicity (e.g., peracute, acute, chronic). 
Unfortunately, even when a substantial piece of liver tissue is obtained and submitted for 
histopathological examination, pathologists may disagree about the diagnosis.  In situations where 
the histopathological diagnosis does not fit well with the entire clinical picture, the clinician has 
ultimate responsibility to decide whether or not it is necessary to seek the opinion of a second, or a 
subsequent pathologist. 
Collection and submission of liver biopsies for aerobic and anaerobic bacterial culture, rather than 
just for histopathological examination, is sometimes appropriate. 
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Treatment of hepatobiliary diseases – An overview 
 
Surprisingly few studies have been done to evaluate the efficacy (or otherwise) of drugs used to 
treat hepatobiliary disease in dogs and cats.  It would be ideal if randomized, double-blind placebo-
controlled clinical trials formed the basis of many of our treatment choices.  In reality, no such trials 
have been done and most of our clinical decisions are based upon small, non-randomized 
retrospective studies or extrapolations from human medicine based upon a reasonable 
understanding of underlying pathophysiology. 
An international group of veterinary hepatologists is now in the process of standardizing 
nomenclature as a prerequisite for commencing multi-centre collaborative studies.  It is to be hoped 
that, in the coming years, high-quality scientific studies will be carried out and published as peer-
reviewed scientific articles, to allow a much more rational approach to therapy of hepatobiliary 
diseases, one based on high-quality evidence.  However, that is for the future.  Much of what 
follows is based upon rather flimsy evidence, but represents a summary of current practices.  
Glucocorticoids 
It is generally accepted that glucocorticoids have a strong, beneficial effect when used to treat many 
chronic, idiopathic hepatitides–especially in dogs–that are characterized in part by the presence of 
mononuclear and lymphocytic inflammatory infiltrates. In a published retrospective study, treated 
animals went into complete remission, did not relapse, and survived much longer than untreated 
animals.  The clinical experience of numerous veterinarians further supports the use of 
glucocorticoids for treatment of chronic, idiopathic hepatitides (e.g., prednisolone, 1-2 mg/kg SID 
initially, then decreased to EOD and tapered gradually while monitoring for relapse). 
The apparent efficacy of glucocorticoids and the observed inflammatory cell infiltrates are 
consistent with the possibility that immune (perhaps autoimmune) pathomechanisms are operational 
in some animals with chronic, idiopathic hepatitis.  It has been conjectured that an acute insult (e.g., 
infection by a presently uncharacterized infectious agent) and consequent hepatic tissue damage 
may lead to exposure of autoantigens and subsequent autoimmune attack upon the liver.  During the 
chronic phase of liver disease, the infectious agent may be long gone (i.e., a hit-and-run disease 
mechanism may be operational). 
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Glucocorticoids should probably not be used to treat acute idiopathic hepatitides, since some 
affected animals may have as yet uncharacterized infections.  Glucocorticoids are contraindicated in 
many infectious diseases and irrelevant in others. Supportive care is usually sufficient for 
management of acute, idiopathic hepatitides. 
Although glucocorticoids have some anti-fibrotic and choleretic (i.e., bile flow stimulating) effects, 
it has been suggested that there are other drugs that are more potent, if these effects are needed or 
desired. 
Azathioprine 
This immunosuppressant drug (1-2 mg/kg SID to EOD) may also be used for chronic, idiopathic 
hepatitis.  It has the advantage that it does not cause many of the adverse effects of glucocorticoids 
(e.g., PU/PD, panting, ravenous hunger, steroid hepatopathy).  However, it can sometimes cause 
myelosuppression.  It may be used in combination with prednisolone in dogs to allow the dose of 
glucocorticoid to be decreased somewhat.  It is not recommended for use in cats, since it can cause 
more severe adverse effects in this species.  Melphalan could perhaps be used instead. 
Ursodiol  (Ursodeoxycholic acid) 
This hydrophilic bile acid is choleretic, i.e. it stimulates increased bile flow.  It is administered 
orally (15 mg/kg PO SID or divided BID) and is recommended for use in patients that have chronic 
intrahepatic cholestasis without bile duct obstruction.  Ursodeoxycholic acid, being hydrophilic, is a 
relatively harmless bile acid and is thought to displace more pathogenic, hydrophobic bile acids 
from the recirculating pool.  Removal of hydrophobic bile acids from the recirculating pool is 
thought to diminish the ‘detergent-like’ action of hydrophobic bile acid excess that causes 
hepatocyte membrane injuries, oxidative damage and induction of apoptosis in hepatocytes. 
Ursodiol is also used for many other forms of feline and canine liver disease, although it has not 
been proven to be effective in any of them.  It has immunomodulating effects and increases the 
hepatic production of glutathione and metallothionein.  It may thus serve as an antioxidant. 
Lathyrogenic (anti-fibrotic) drugs 
Probably the most effective way to slow the progression of liver fibrosis is to attack the underlying 
process (usually inflammatory) that is leading to the fibrosis.  Thus, glucocorticoids and 
azathioprine may have anti-fibrotic effects in some patients.  Colchicine (0.025-0.03 mg/kg/day; 
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benefit unproven) is a drug advocated for the purpose of diminishing hepatic fibrosis.  It is thought 
to stimulate collagenase activity.  Unfortunately, it has a reputation for causing nausea, vomiting 
and diarrhoea in dogs although the true extent of this problem is unknown.  In humans, it can be 
very toxic and small, single overdoses have led to deaths.  There is insufficient evidence that 
colchicine truly has an anti-fibrotic effect .  Some authorities suggest that colchicine should not be 
used until evidence to support its use is published. 
Drugs to combat copper accumulation and its effects 
Various drugs have been used for the treatment of hepatopathies associated with copper 
accumulation.  The best characterized of these copper-accumulation hepatopathies is the one found 
in Bedlington terriers.  This is reported to be an autosomal recessive disorder that leads to the 
progressive accumulation of copper in the liver and eventually to liver damage.  It was once 
believed that this Bedlington disorder was a perfect model for human Wilson’s disease, but this has 
been disproven.  Affected dogs accumulate copper in their livers gradually over time.  Liver copper 
content may gradually rise to be as high as 12,000 ppm dry weight in affected Bedlington terriers.  
There is a progressive increase in copper accumulation until 8 years of age.  An acute haemolytic 
crisis sometimes develops in affected dogs, as a consequence of copper release from the damaged 
liver. 
Fuentealba IC, Aburto EM. Animal models of copper-associated 
liver disease. Comparative Hepatology 2003; 2(1):5. 
This article is available for free from: 
http://www.comparative-hepatology.com/content/2/1/5 
Copper-accumulation hepatopathies are also seen in other breeds (e.g., West Highland white terrier, 
Skye terrier, Dalmatian, Doberman pinscher, Turkish shepherd dog).  In some of these, copper 
accumulation is thought to be a primary event and in others it is secondary to chronic cholestasis or 
other metabolic defects within the liver. 
D-Penicillamine 
D-Penicillamine is an orally administered chelating agent that binds copper and some other heavy 
metals.  It is dosed at 10-15mg/kg PO BID and given 30 minutes before feeding or, if nausea 
develops, at the time of meals.  It is the best characterised copper chelating drug and is still widely 
used and recommended.  It must be given for several months to have any beneficial effects.  It is 
capable of removing copper, gradually, from the liver.  It does this by binding extracellular copper, 
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which is subsequently excreted in the urine.  Free, intracellular copper then moves out of cells to 
equilibrate and gradually excess copper is cleared from hepatocytes. 
2,2,2 tetramine tetrahydrochloride (Trientene) 
This is an alternative copper chelating agent that is sufficiently potent that it may eventually cause 
copper depletion.  It is dosed at 10-15 mg/kg BID, with meals.  It may cause nausea and vomiting if 
given on an empty stomach. 
Zinc gluconate or Zinc acetate 
Zinc (10mg elemental zinc/kg BID, one hour before feeding) induces the expression of 
metallothionein in intestinal epithelial cells.  This induced protein binds dietary copper and the 
complex is excreted (in sloughed enterocytes) in the faeces.  Zinc can be thought of as a way of 
preventing further copper accumulation.  In most animals with pre-existing copper accumulation, it 
is appropriate to treat with a chelator for about three months and then switch to the use of zinc.  
Chelators and zinc should not be used at the same time, since the chelator will bind to the zinc and 
render both drugs ineffective. 
Other drugs 
Free cytosolic copper induces oxidative damage in the hepatocyte, particularly to the mitochondria.  
Therefore, antioxidant medications may have a place in the management of some patients with 
copper accumulation hepatopathy.  This is particularly true if a haemolytic crisis develops.  
Antioxidant medications are described in the next section. 
Antioxidant drugs 
Oxygen free radicals and so-called oxidative stress play an important role in initiation and 
perpetuation of many hepatobiliary diseases.  For example, free copper within the cytosol of 
hepatocytes can lead to the production of free radicals and oxidative damage.  The hepatotoxicities 
of paracetamol and Death Cap mushrooms (Amanita phalloides) centre upon oxidative damage.  
Free radicals are generated within hepatocyte mitochondria.  Since hepatocyte mitochondrial 
membranes are damaged by elevated bile acid concentrations in many cholestatic disorders, 
cholestasis can lead to hepatic injury, in part, by causing oxidative damage.  Activated macrophages 
also produce free radicals, so many inflammatory hepatic disorders are associated with oxidative 
damage. 
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The body has defence mechanisms against oxidative stress, including superoxide dismutase (SOD) 
and glutathione (GSH) peroxidase. These defences, however, may be overwhelmed in the face of 
severe oxidative challenge. Antioxidant therapy has been proved to be beneficial in paracetamol 
and Death Cap mushroom poisoning.  It is very likely to be helpful in Bedlington terriers with 
haemolytic crisis.  In many other hepatic disease situations, antioxidant therapy is a little more 
speculative, but may provide benefit. 
Silymarin (extract of Milk thistle, Silybum marianum) 
Silymarin is a collective term for a number of active compounds found in the milk thistle plant.  
Milk thistle has been used for centuries as a treatment for hepatobiliary disorders.  Silymarin has 
been shown to be a potent free radical scavenger and it increases hepatocyte SOD levels.  Several 
studies have shown that it has potent, sometimes life-saving effects when used in patients poisoned 
by Death Cap mushrooms or paracetamol.  How long after such intoxications silymarin can be 
given, and still exert a life-saving effect, is uncertain.  Silymarin may also have a useful role in 
treatment of copper accumulation hepatopathy although no studies have been done to demonstrate 
added benefit on top of chelator therapy.  The potency of silymarin has not been directly compared 
with that of other antioxidants drugs such as the ones that follow immediately. 
Vitaglione P, Morisco F, Caporaso N, Fogliano V.  Dietary 
antioxidant compounds and liver health.  Critical Reviews in 
Food Science and Nutrition 2004;44(7-8):575-86.  
 
s-Adenosyl-L-methionine (SAMe) 
SAMe is present in normal hepatocytes, being a precursor of cysteine, which in turn is a precursor 
of the tripeptide glutathione (GSH).  GSH is very important in combating oxidative stress.  GSH 
may be depleted in the face of overwhelming oxidative challenge.  If SAMe production were 
compromised in the damaged liver, inadequate production of GSH might be a consequence.  
Therefore, administration of exogenous SAMe may help to restore GSH production and combat 
oxidative damage.  One study has shown that in 45% of dogs and cats with liver disease GSH levels 
were sub normal. However, the efficacy of SAMe not been directly demonstrated in dogs and cats 
with liver disease. 
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Others  
As well as its copper-reducing properties, zinc has antioxidant properties.  For this purpose, lower 
doses are recommended (2-3 mg/kg/day elemental zinc).  Ursodiol also seems to protect 
hepatocytes from oxidative injury by increasing hepatocyte levels of GSH and metallothionein.  
Vitamins E and C are well-known dietary antioxidants, although at high concentrations vitamin C 
can be pro-oxidant.  Alpha-tocopherol (vitamin E; 15IU/kg/day) is a lipid-soluble, dietary 
constituent that is absorbed from the gastrointestinal tract and found membrane-bound in 
hepatocytes.  It can protect against membrane peroxidation.  Ascorbic acid (vitamin C) is a water-
soluble antioxidant.  It can reactivate oxidised vitamin E.  Unlike humans, dogs and cats can 
synthesise their own vitamins C and E.  There is no evidence that levels are deficient in canine and 
feline hepatobiliary diseases. 
 
Medical management of hepatic encephalopathy (HE) 
Rational management of HE is based upon an understanding of the underlying pathophysiology.  
Here is an article written fairly recently (2001) concerning HE in humans and available for free via 
the Web.  The underlying pathophysiology in humans and animals is quite similar:- 
http://www.postgradmed.com/issues/2001/02_01/assi.htm  
If the underlying cause of HE can be resolved (for example, by surgical management of a PSVA) 
this is the most effective way of dealing with the problem.  Temporary medical management is 
often necessary, even if surgical management is being planned. Since the source of ammonia and 
other compounds that cause HE is the gastrointestinal tract, many of the therapeutic interventions 
focus on changing the environment within the intestines. 
A special diet with reduced total protein content and more substantial reduction of aromatic amino 
acids should be used.  Sources of gastrointestinal haemorrhage (e.g., parasites, ulcers) should be 
treated or removed, if possible.  Lactulose (5-30ml PO TID until the stools are slightly soft), a 
synthetic disaccharide, should be given.  This osmotic laxative will hasten gastrointestinal 
emptying, allowing less time for absorption of ammonia produced in the colon by intestinal 
bacteria.  More importantly, fermentation of lactulose lowers intestinal pH, trapping ammonia (as 
ammonium ions) in the colonic contents, and changing the colonic bacterial flora favourably.  An 
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antibiotic that is not absorbed from the intestinal tract and is active against urea-splitting bacteria 
(e.g., neomycin) is also useful in some patients. 
The use of benzodiazepine drugs is generally to be avoided in patients with HE, since endogenous 
benzodiazepine-like substances contribute to the pathogenesis of HE.  HE is worsened by 
hypokalaemia, so attention should be paid to avoiding this electrolyte abnormality.  Alkalosis is 
also to be avoided, because it can increase the likelihood of hypokalaemia developing (because 
potassium ions move intracellularly to replace hydrogen ions when these exit cells in response to 
alkalaemia). 
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Selected hepatobiliary conditions – key points 
Inflammatory / infectious hepatobiliary diseases 
Canine chronic hepatitis 
• Strictly, ≥6 months’ duration with hepatocellular necrosis and a predominantly 
lymphoplasmacytic inflammatory infiltrate.  Typically progresses to fibrosis and cirrhosis. 
The cause may be evident (e.g., primary copper accumulation), but most are idiopathic.  
Typically associated with persistent elevation of serum ALT and ALP until very advanced 
disease leads to decreasing enzyme levels.  ALT is usually more impressively elevated than 
ALP (versus steroid hepatopathy).  In severe, advanced cases icterus may be present. 
• Female Doberman pinschers and male cocker spaniels are at increased risk.  Other breeds 
reported to be overrepresented include Bedlington terriers, West Highland white terriers, 
Dalmatians, Skye terriers, standard poodles, Labrador retrievers, German shepherd dogs, 
Scottish terriers, and beagles.  In some of these breeds, primary copper accumulation is likely 
to be the underlying cause. 
• Typical clinical signs in advanced cases include lethargy, depression, inappetence, weight 
loss, PU/PD and vomiting.  Disease may be detected before the signs become evident if a 
serum biochemistry profile is assessed for some reason. 
• Definitive diagnosis requires a liver biopsy.  Lymphoplasmacytic inflammation and piecemeal 
necrosis are essential features.  Fibrosis is a feature of advanced disease.  Bridging fibrosis* 
and nodular regeneration (i.e. cirrhosis) indicate very severe, advanced disease.  Copper 
accumulation and vacuolar hepatopathy may be present. 
• Treatment usually consists of glucocorticoids (± azathioprine), antioxidants and ursodiol.  H-2 
receptor blockers may be appropriate to help reduce gastrointestinal ulceration in some 
patients.  If copper accumulation is severe enough, chelation therapy and or zinc therapy are 
indicated.  Specific anti-fibrotic therapy (i.e., colchicine) is suggested by some authors and 
considered contraindicated by others.  Many of the other drugs mentioned above have anti-
fibrotic activity. 
                                                 
* there are bridges of fibrous tissue extending between liver lobules.  Bridging fibrosis may cause permanent distortion of the liver’s architecture and 
be associated with regenerative nodules.  This is called cirrhosis. 
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Doberman pinscher chronic hepatitis 
Middle-aged, female Doberman pinschers are at increased risk to develop a severe form of chronic 
hepatitis with consequent cirrhosis.  Sometimes this goes completely unnoticed until the dog suffers 
gastrointestinal haemorrhage at which point HE might develop.  On other occasions, the diagnosis 
is made when dogs are investigated for PU/PD.  Affected dogs may have high liver copper 
concentrations, but it is thought that copper accumulation is secondary to inflammation and 
cholestasis in this disease. 
Copper accumulation in Bedlington terriers 
The copper accumulation hepatopathy of Bedlington terriers is autosomal recessive and thought to 
be caused by a deletion of exon 2 in the MURR1 gene.  The Bedlington disease differs somewhat 
from true Wilson’s disease of humans.    
Favier RP, Spee B, Penning LC, Brinkhof B, Rothuizen J.  
Quantitative PCR method to detect a 13-kb deletion in the 
MURR1 gene associated with copper toxicosis and HIV-1.  
Mammalian Genome 2005; 16(6):460-3. 
Affected Bedlington terriers gradually accumulate copper in their livers, with levels occasionally 
reaching a staggering 12,000 ppm of liver tissue. Above 2000 ppm, mitochondrial damage to 
hepatocytes is likely to occur with consequent inflammation and serum ALT elevation.  When liver 
copper levels have risen sufficiently, modest stress is sufficient to induce acute hepatic necrosis and 
haemolysis.  Renal failure may develop.  In animals over eight years of age, liver copper content 
tends to decrease, probably because copper-laden hepatocytes are replaced by fibrous tissue. 
Early detection offers the best chance of helping affected animals. Chelation therapy may be needed 
if sufficient copper has already accumulated.  After that, lifelong zinc administration can be used to 
help affected animals live a normal life. 
In some countries, selective breeding has dramatically decreased the prevalence of this disease.  In 
future, a robust genetic test for detection of affected animals and carriers is likely to become 
commercially available.  Meanwhile, liver biopsies are being taken at 6 and 15 months of age and 
used to distinguish normal animals from heterozygotes and homozygous affected animals.  The 
liver copper concentration is high on the first biopsy and increases on the second biopsy in 
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homozygous affected animals.  It is abnormally high on the first biopsy but decreases by the second 
biopsy in heterozygotes.  It is, of course, normal in unaffected animals. 
Infectious canine hepatitis 
This acute viral disease is caused by Canine adenovirus.  Largely as a consequence of widespread 
vaccination, it has become very uncommon in many parts of the world. It has been suggested that 
canine adenoviral infection may underlie some cases of chronic hepatitis in dogs, but there is little 
evidence to support the suggestion. 
Leptospirosis 
Some dogs with leptospirosis develop acute or subacute renal failure without jaundice, but in many 
the liver is involved.  Fever, jaundice and increased liver enzymes in the dog that has concurrent 
renal failure suggest the possibility of leptospirosis.  One serovar of L. interrogans (grippotyphosa) 
has been implicated as a possible cause of chronic hepatitis in dogs. 
 
Feline Cholangitis / changiohepatitis complex 
Caney SMA, Gruffydd-Jones TJ. Feline inflammatory liver 
disease. In: Ettinger, SJ; Feldman, EC. (Eds.) Textbook of 
Veterinary Internal Medicine, Sixth Edition. St Louis, Mo: 
Elsevier/Saunders, 2005; 1448-1453. 
This is probably the most common primary liver disorder (or cluster of disorders) in British cats.  
Cases can be broadly categorized as either suppurative or lymphocytic. 
Suppurative cholangitis and cholangiohepatitis 
• Predominantly neutrophils infiltrating the bile ducts, which show necrosis and 
degeneration.  Variable fibrosis.  Thought to arise as a result of ascending bacterial 
infection.  Mixture of enteric bacteria can usually be cultured from bile of affected cats. 
• Often accompanied by mild pancreatitis, which can also be caused by ascending bacterial 
infection (N.B. the anatomy of the feline pancreatic & common bile ducts). Even more 
often accompanied by inflammatory bowel disease (IBD; usually lymphoplasmacytic, but 
sometimes suppurative).  Hence (if all three entities present concurrently) the use of the 
term triaditis.  Maybe IBD ? ascending infection ? pancreatitis and cholangitis. 
• ‘Triaditis’ usually manifests clinically as cholangitis. 
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• Clinical features: An acute onset disease of middle-aged to older cats (often >10 years).  
No sex or breed predilection.  Anorexia, ±pyrexia, icterus (due to intrahepatic cholestasis  
±sludge causing EHBDO), ± abdominal discomfort. 
• Diagnosis: ↑ ALT and bilirubin.  ± ALP, γ-GT and SBA elevations.  Increased PIVKAs.  
Ultrasound reveals gallbladder distension ± thickening.  Prominent ± thickened bile ducts.  
Sometimes cholelithiasis.  Histopathology required for confirmation.  Laparotomy allows 
biopsy of liver, intestine and pancreas; plus aspiration and culture of bile. 
• Therapy: Amoxicillin-clavulanate pending culture results.  Fluoroquinolone / 
metronidazole may be needed.  4-6 weeks of antibiotics. Ursodiol ±SAMe.  Surgery if 
complete EHBDO. Supportive measures. 
• Prognosis: In one study, half survived more than a year (median survival 29 months).  
Prognosis influenced by concurrent illnesses.  Much worse if surgical anastomosis to deal 
with EHBDO is required. 
Lymphocytic cholangitis 
• Predominantly T-lymphocytic inflammatory infiltrates surrounding bile ducts and within 
portal areas. Suspected to be an immune-mediated disease. 
• Bile duct proliferation, maybe with inflammation but no epithelial degeneration.  Variable 
fibrosis, sometimes severe.  Secondary nodular hyperplasia. 
• Association with IBD and pancreatitis much less strong than for suppurative cholangitis. 
• Considered possibly to be a sequel to suppurative cholangitis, but seen in younger cats, less 
associated with pancreatitis / IBD, no history of previous liver disease reported for most 
affected cats. 
• Clinical features:  >50% under 4 years old. Persians overrepresented.  Much more common 
than the suppurative disease.  Present as icteric cats or cats with worsening ascites; maybe 
both.  Do not look very sick; indeed may be hungry.  ±weight loss, ±palpable hepatomegaly. 
• Diagnosis:  Liver enzymes and bile acids elevated. ± hyperbilirubinaemia and 
hyperglobulinaemia.  Lymphopenia. Ascitic fluid, if present, reminiscent of that in FIP.  
Histopathology required for confirmation and, sometimes, to distinguish from FIP. 
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• Treatment:  Prednisolone 1-2 mg/kg BID gradually tapering over 6–12 weeks. ± other 
immunosuppressant drugs.  ± Ursodiol, SAMe.  
• Prognosis:  Limited information available, but seems to be fairly good. 
 
Metabolic and toxic liver diseases 
Scherk MA, Center SA. Toxic, metabolic, infectious and 
neoplastic liver diseases.  In: Ettinger, SJ; Feldman, EC. 
(Eds.) Textbook of Veterinary Internal Medicine, Sixth 
Edition. St Louis, Mo: Elsevier/Saunders, 2005; 1464-1478. 
Canine vacuolar hepatopathy 
As previously mentioned, the canine liver responds to exogenous glucocorticoid administration by 
induction of liver enzymes, particularly ALP.  Morphological changes accompany or follow these 
enzymatic changes.  Progressive accumulation of glycogen in hepatocytes occurs, leading over time 
to enlargement of the liver and obvious vacuolar changes visible on microscopic examination of 
routine H&E stained liver biopsies.  This glycogen accumulation is reflected as a diffuse increase in 
overall echogenicity of the liver, when viewed using ultrasound. 
Excessive endogenous production of steroids (such as glucocorticoids and sex steroids) can lead to 
an identical effect.  Thus, the various forms of hyperadrenocorticism can cause vacuolar 
hepatopathy.  However, not all dogs diagnosed with vacuolar hepatopathy are demonstrably 
Cushingoid.  It is thought that the stress associated with a variety of non-adrenal illnesses can, in 
some animals, lead to sufficient excessive glucocorticoid secretion to cause vacuolar hepatopathy 
and (usually) serum ALP elevation.  In other animals that have negative test results for 
hyperadrenocorticism, sex steroids produced by hyperplastic adrenal glands may be responsible for 
the vacuolar hepatopathy.  Sex hormone profiles can be done before and after ACTH administration 
to assist in diagnosis of such cases.  One author has suggested that mitotane treatment of affected 
animals should be considered, since vacuolar hepatopathy may occasionally progress to more 
severe disease and be associated with hepatocutaneous syndrome. 
Feline hepatic lipidosis 
This condition is common and very important in the United States but much less so in UK.  Its 
pathogenesis is complex and incompletely understood.  It is only described superficially here.   Ill 
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cats tend to accumulate triglycerides in their hepatocytes leading to visible fatty vacuolation.  This 
causes no significant problems until it becomes markedly severe.  Obese cats that become anorexic 
are at greatest risk of developing hepatic lipidosis.  In such cats, peripheral fat is mobilized and 
excessive fat is taken up by the liver but is not dispersed properly. A variety of defects in hepatic 
function may then come into play, hampering formation of very low-density lipoproteins and fat 
dispersion. L-carnitine deficiency, vitamin B12 deficiency (perhaps associated with intestinal 
disease), GSH deficiency and unavailability or failure to use SAMe have all been proposed to be 
relevant. 
Cats of any age can be affected, especially those 4–15 years old.  Clinical signs are initially non-
specific: anorexia, lethargy, weight loss and vomiting.  Icterus and hepatomegaly may be 
appreciated on physical examination.  The serum chemistry profile reveals elevated ALP and ALT, 
but usually mild or no elevation of γ-GT.  Bilirubin may be elevated.  Hypokalaemia is common 
and should be treated, if present.  Ultrasound usually reveals a diffusely hyperechoic liver 
parenchyma.  FNA will typically reveal the vacuolar change.  Diagnostic investigations may also 
reveal a distinct underlying cause for the hepatic lipidosis, although many cases remain idiopathic. 
Treatment usually involves placement of a feeding tube (e.g., gastrostomy, oesophagostomy) and 
provision of a balanced diet at 60 kcal/kg/day, often provided in multiple very small portions, or as 
a ‘constant infusion’.  Intravenous fluid therapy is provided with water-soluble vitamins added.  
Supplementation of potassium and phosphate may be necessary. 
Vitamin K1 (0.5-1.5 mg/kg SC BID), L-carnitine (250-500 mg/day), taurine (250-500mg/day) and 
antioxidants may also provide benefits and have been recommended for use.  
Hepatotoxicities 
Numerous drugs, herbal remedies and poisons can cause hepatic damage.  The toxic effects of some 
of these agents are ‘intrinsic’ (i.e., a direct effect, reliably to be expected) and, for others, toxicity is 
idiosyncratic, sometimes being immune-mediated.  The distribution of lesions within hepatic acinar 
units can sometimes be informative as to the likely cause of a toxic insult. 
You should aim to find and read one or two paragraphs of supplemental information about each of 
the hepatotoxicities caused by the following drugs or groups of drugs (Ettinger & Feldman is one 
good source of information):- 
• Anticonvulsants (e.g., phenobarbital) 
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• Antimicrobials (e.g., trimethoprim-sulpha, ketoconazole) 
• Diazepam 
• Methimazole / carbimazole 
• NSAIDs (carprofen, paracetamol) 
 
Portosystemic vascular anomalies (PSVAs) 
Mathews KG, Bunch SK. Vascular liver diseases. In: Ettinger, 
SJ; Feldman, EC. (Eds.) Textbook of Veterinary Internal 
Medicine, Sixth Edition. St Louis, Mo: Elsevier/Saunders, 
2005; 1453-1464. 
• PSVAs are congenital anomalies that may be intrahepatic or extrahepatic in location.  In 
general, small breed dogs are prone to extrahepatic shunts and large breed dogs are prone to 
intrahepatic ones. Extrahepatic shunts are more common.   Most extrahepatic shunts are single 
aberrant vessels.  Many intrahepatic shunts represent patent ductus venoses that failed to close 
early in life. 
• Clinical features are a consequence of portal blood circumventing the liver.  The systemic 
circulation is exposed to toxins and bacteria that would normally be filtered by the liver.  The 
liver is deprived of trophic factors and oxygenated blood. 
• PSVAs are much less common in cats than in dogs.  Most feline PSVAs are single and 
extrahepatic.  Himalayans and Persians are predisposed to develop PSVAs.  Clinical features 
observed in cats include staring into space, aggression, intermittent blindness and intermittent 
salivation. 
• Partial attenuation of PSVAs, rather than complete occlusion in one procedure, is usually 
necessary to avoid life-threatening portal hypertension.  A variety of surgical approaches has 
been advocated for gradual attenuation of extrahepatic PSVAs.  These include cellophane bands 
and ameroid constrictor rings.  Some surgeons advocate the use of a n intravenous catheter, 
extension set and water manometer during surgery, for measurement of portal hydrostatic 
pressure to help judge how much the aberrant vessel should be attenuated. 
• Up to 3 days post-operatively, status epilepticus occasionally develops and can be life-
threatening. This is reportedly more frequently observed in older animals, whose brain 
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chemistry has had time to adapt to the presence of benzodiazepine-like substances and perhaps 
other neurotoxins from the gut. 
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Exocrine pancreatic disorders – key points 
Pancreatitis in dogs and cats 
Watson P. Laboratory evaluation of exocrine pancreatic 
disease. In: E. Villiers & L. Blackwood (Eds.) BSAVA Manual 
of Canine and Feline Clinical Pathology, Second Edition. Pp. 
226-240. 
Williams DA, Steiner JM. Canine exocrine pancreatic disease.  
In: Ettinger, SJ; Feldman, EC.. (Eds.) Textbook of Veterinary 
Internal Medicine, Sixth Edition. St Louis, Mo: 
Elsevier/Saunders, 2005; 1482-1488. 
Steiner JM, Williams DA. Feline exocrine pancreatic disease.  
In: Ettinger, SJ; Feldman, EC.. (Eds.) Textbook of Veterinary 
Internal Medicine, Sixth Edition. St Louis, Mo: 
Elsevier/Saunders, 2005; 1489-1492. 
Pancreatitis is a relatively common diagnosis in dogs and is being diagnosed with increasing 
frequency in cats.  The true incidence of pancreatitis in dogs and cats is uncertain.  It is likely that 
many cases are missed and, conversely, pancreatitis may sometimes be diagnosed incorrectly in 
patients with other gastrointestinal diseases. 
The fundamental mechanism of disease in pancreatitis is autodigestion of pancreatic tissue by 
digestive enzymes that are prematurely activated within the pancreatic acinar cells.  Normally, 
pancreatic digestive enzymes are released from the pancreas as inactive zymogen granules.  
Trypsinogen within these granules is proteolytically cleaved and activated when it reaches the 
duodenal lumen by an enzyme called enteropeptidase (prev. enterokinase).  The newly-formed 
trypsin is then able to activate other zymogens by proteolytically cleaving from each a small amino 
terminal peptide called the ‘activation peptide’.  In acinar cells, the developing granules are 
normally strictly kept separate from lysosomes.  In many experimental models of acute pancreatitis, 
zymogen granules fuse abnormally with lysosomes inside acinar cells leading to inappropriate intra-
pancreatic activation of the zymogens.  Lysosomes contain proteases that, at low pH, are capable of 
activating the zymogens.  For protection, the pancreas contains trypsin inhibitors and trypsin can 
autocatalyze its own degradation.  However, the inhibitor present in zymogen granules is not active 
at the low pH present in lysosomes. If the zymogen activation process proceeds too vigorously, 
pancreatitis can  result. 
Pancreatitis can have severe, adverse systemic effects because activated proteolytic enzymes can 
circulate and cause damage distant from the pancreas.  There are plasma protease inhibitors (e.g., 
alpha-macroglobulins and alpha-1-proteinase inhibitor) that bind and inactivate circulating 
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proteases and lead to their rapid clearance from circulation by the mononuclear phagocyte system.  
Unfortunately, these plasma protease inhibitors can be consumed in severe pancreatitis.  This is one 
reason why fresh-frozen plasma transfusions can sometimes be life-saving in severe pancreatitis. 
Some of the ways in which pancreatitis can be reproduced experimentally include: 1). 
hyperstimulation of secretion; 2). obstruction of the pancreatic duct; and 3). retrograde, intraductal 
injection of bile or duodenal enzymes.  These mechanisms may also be relevant in clinical 
situations.  For example, in high-rise syndrome of cats retrograde flow of duodenal contents into the 
pancreatic duct may occur.  Alternatively, blunt trauma to the pancreas may lead to ischaemic 
damage and consequent pancreatitis.  In cats, viscous bile may lead to EHBDO.  Remember that the 
pancreatic duct joins the bile duct before entering the duodenum in cats, meaning that biliary 
diseases more readily extend to involve the pancreas in this species. 
In many patients with pancreatitis, the underlying cause for development of the disease is never 
defined.  Some risk factors that are well-recognised, but not necessarily well understood, include:- 
• Ductal obstruction; 
• Hyperlipidaemia (e.g., familial forms); 
• Dietary indiscretion (e.g., a recent very fatty meal); 
• Physical trauma (e.g., high-rise syndrome, blunt abdominal trauma, surgery); 
• Hypercalcaemia; 
• Ischaemia / reperfusion / hypoxaemia (e.g., gastric dilatation-volvulus, profound anaemia); 
• Various drugs and toxins (e.g., organophosphates, azathioprine, L-asparaginase, tetracycline 
potassium bromide); and 
• Infections / infestations (e.g., Toxoplasmosis, FIP, hepatic fluke [Amphimerus pseudofelis]). 
 
In cats, as previously mentioned, pancreatitis commonly accompanies 
cholangitis/cholangiohepatitis and IBD.  In dogs, pancreatitis is thought to be more common in 
obese animals. 
 
Diagnosis 
Pancreatitis is most common in middle-aged and older dogs that are often overweight.  In cats, a 
much wider age range may be affected. Dogs with acute pancreatitis usually have vomiting, 
abdominal pain, depression and sometimes fever and diarrhoea.  Peracute disease may be associated 
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with stupor, collapse and rapidly progressive deterioration in haemodynamic status. Signs of DIC 
(e.g., petechiae, ecchymoses) may develop within hours. In subacute or chronic cases, a cranial 
abdominal mass may be palpable after one or two days.  This can sometimes be quite firm, and 
maybe associated with peripancreatic fat saponification.  
Cats usually have less obvious clinical signs and dogs with lethargy, anorexia and weight loss 
predominating.  The disease can also vary enormously in severity.  Vomiting and abdominal pain 
are absent in a majority of affected feline patients. 
Radiography may be helpful in dogs, but only in a minority of affected patients.  There may be 
increased radiopacity and reduced contrast in the right cranial abdomen (with a so-called ‘ground 
glass’ appearance).  The descending duodenum may be displaced to the right and have some gas in 
it.  This gas may be persistently present on more than one radiograph. Sometimes the gas within the 
duodenum reveals a corrugated 'angry' appearance to the descending duodenum, or the impression 
of thickened duodenal walls.  Similar changes may also be detected in the ascending/transverse 
colon. 
Animals were severe pancreatitis may have a pleural effusion, more likely to be observed on the 
right side. 
Ultrasonography can be highly specific for diagnosis of pancreatitis in the hands of an expert 
operator, but sensitivity is rather low.  It ranges from 70% in dogs to as low as 30% in cats. 
Ultrasonographic diagnosis of pancreatitis is particularly challenging in cats because many have 
mild or chronic morphological changes.  Contrast enhanced computed tomography in cats has been 
reported to be even less sensitive than ultrasonography for the detection of pancreatitis. 
Peripheral blood neutrophilia, often with a left shift, is a common feature of pancreatitis.  
Thrombocytopenia, if present, may be evidence of developing DIC.  Azotaemia may be present.  It 
may be prerenal or renal, since pancreatitis can induce secondary acute renal failure.  This form of 
acute renal failure can resolve if the pancreatitis is successfully managed.  Liver enzymes are 
usually increased as a consequence of local inflammation and flow of toxins in venous blood from 
the inflamed pancreas to the liver.  EHBDO may develop because of external pressure on the 
common bile duct.  This can lead to hyperbilirubinaemia, hyperbilirubinuria and sometimes icterus.  
Cholestasis of sepsis may contribute to hyperbilirubinaemia and icterus in some patients.  
Hyperglycaemia may be present as a result of stress and, in some patients, islet-cell destruction.  
Hypoalbuminaemia and hypocalcaemia may develop.  Low blood calcium may only reflect the 
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albumen concentration or may be a consequence of calcium consumption in peripancreatic soap.  
Hypoalbuminaemia may be a consequence of inflammation (remember, it is a negative acute phase 
reactant) or loss of albumin from blood vessels into the extracellular space and into ‘third spaces’ 
(e.g., peritoneal cavity, oral cavity) as a result of pancreatitis-induced vasculitis.  Hyperlipidaemia 
may be present despite anorexia and may interfere with a measurement of many other serum 
biochemical analytes. 
Serum amylase and lipase have been used for many years in the assessment of suspected 
pancreatitis.  Unfortunately, they far from ideal for this purpose.  In one study, the sensitivity and 
specificity of elevated serum amylase for detection of canine pancreatitis were 62% and 57%, 
respectively.  For elevated serum lipase the sensitivity and specificity were 73% and 55%, 
respectively.  In pancreatitis, these enzymes may become depleted or their synthesis may be 
disrupted.  This may explain the poor sensitivity values and also why the severity of clinical disease 
does not correlate well with the degree of enzyme elevation.  The poor specificity values may be 
explained by sources of enzyme outside the pancreas, failure of clearance of serum enzyme in renal 
failure and glucocorticoid-induced increases in serum lipase activity, in the absence of pancreatitis.  
In contrast, glucocorticoids are reported to decrease serum amylase activity. 
Measurement of amylase and lipase activities in peritoneal effusion fluid, or fluid obtained by 
peritoneal lavage, has been suggested and is used by many clinicians.  Whether it provides 
advantages over measuring serum activities is uncertain. 
In cats, measurement of serum amylase and lipase activities has no diagnostic usefulness. 
Serum trypsin-like immunoreactivity (TLI) is familiar to many companion animal veterinarians 
because it is used in the diagnosis of canine (and more recently feline) exocrine pancreatic 
insufficiency (see later).  Unfortunately, TLI is an insensitive way of assessing dogs and cats with 
naturally-occurring pancreatitis.  Elevated levels were observed in less than 40% of dogs and 30-
60% of cats with naturally-occurring pancreatitis.  It has high specificity except in azotaemia cats. 
A relatively new kind of test detects serum pancreatic lipase immunoreactivity in both cats (fPLI) 
and dogs (cPLI).  Unfortunately these can only be measured in Texas, although British clinical 
pathology labs will forward samples.  The reference range for serum cPLI is reportedly 2.2–102 
µg/L. Using a cut-off value of 200µg/L, the test was 82% sensitive and 100% specific.  In cats, fPLI 
detection is reported to be sensitive and specific in the diagnosis of pancreatitis. 
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Treatment 
In severely affected patients this can be very challenging.  Here as a summary list of things to 
consider in most cases:- 
• Removal of any identified underlying cause 
• Analgesia 
• Intravenous crystalloid fluid therapy, with monitoring of electrolytes and acid-base status in 
severely ill patients 
• Insulin if diabetic 
• Plasma or whole blood transfusion in severely ill patients 
• Control of vomiting 
• Offer water and if vomiting does not follow, provide enteral nutrition with a fat-restricted, 
highly digestible food.  In cats, tube feeding is likely to be necessary. 
 
 
Exocrine pancreatic insufficiency (EPI) 
Watson P. Laboratory evaluation of exocrine pancreatic 
disease. In: E. Villiers & L. Blackwood (Eds.) BSAVA Manual 
of Canine and Feline Clinical Pathology, Second Edition. Pp. 
226-240. 
Westermarck E, Wilberg /M, et al.  Exocrine pancreatic 
insufficiency in dogs and cats.  In: Ettinger, SJ; Feldman, 
EC.. (Eds.) Textbook of Veterinary Internal Medicine, Sixth 
Edition. St Louis, Mo: Elsevier/Saunders, 2005; 1492-1495. 
EPI is uncommon to rare in cats and much better characterized in dogs.  In cats, it is most often 
caused by chronic pancreatitis. 
In dogs, EPI may arise because of selective loss of pancreatic acinar cells (PAA), chronic 
pancreatitis and, less commonly, pancreatic hypoplasia or pancreatic neoplasia.  By far the most 
common cause is PAA. 
PAA results from selective destruction or loss of the pancreatic acinar cells with consequent failure 
to produce and secrete pancreatic digestive enzymes.  This results in clinical signs of voluminous 
stools, steatorrhoea, weight loss and (typically) ravenous hunger.  Coprophagia may be a feature. 
Diabetes mellitus is not a feature.  
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PAA is most common in German shepherd dogs and, to a lesser extent, in Rough collies.  In these 
breeds, lymphocytic infiltration of the pancreas has been detected before overt pancreatic 
insufficiency develops.  It is therefore thought that this disease may be immune-mediated or, 
indeed, autoimmune.  For this reason, the name PAA (which stands for pancreatic acinar atrophy) 
should perhaps be discarded and replaced with a name that more accurately describes the suspected 
underlying pathogenesis. 
Diagnosis 
The typical clinical picture is of a young German shepherd dog with pale, voluminous faeces, 
ravenous hunger and weight loss.  Flatulence and intermittent diarrhoea may be reported.  The hair 
coat may be dull. 
Routine blood work does not provide a specific diagnosis.  ALT is often elevated.  This is thought 
to be a consequence of increased gastrointestinal toxins reaching the liver, perhaps as a 
consequence of small intestinal bacterial overgrowth (SIBO). 
Measurement of serum trypsin-like immunoreactivity (TLI) has become the standard way of 
diagnosing EPI.  And abnormally low level (<2.5ng/L in dogs) is found in affected animals. A 
fasting serum sample is required (12 hour fast) to avoid confusion that may be caused by release of 
small amounts of enzyme into the blood during feeding (if the animal has residual pancreatic 
secretory capacity).  The test has excellent sensitivity and specificity and high positive and negative 
predictive values when applied to patients with a compatible clinical picture.  Occasionally, a result 
will be obtained in the grey area (2.5–5.0 ng/L).  Repeat evaluation is recommended in these cases.  
Sometimes such dogs go on to produce clearly positive results but more often the TLI level will 
subsequently be found to be normal.  Sometimes such animals will remain persistently in the 'grey 
area'.  These animals may have chronic, grumbling pancreatitis with marginal exocrine secretory 
capability.  In a non-German shepherd dog with clinical signs strongly suggestive of EPI, a single 
normal TLI value cannot be used to rule out a diagnosis of EPI.  Such dogs may have chronic 
pancreatitis causing EPI.  Pancreatitis tends to cause elevation of serum TLI and EPI, of course, 
lowers it.  These competing influences make it impossible to predict what TLI value will be 
obtained on any particular day. 
There are some other diagnostic tests that can be used for diagnosis of EPI (e.g., faecal proteolytic 
activity, faecal elastase activity), but these have been largely superseded by TLI.  SIBO often 
complicates EPI. Serum cobalamin (vitamin B12) can be measured and supplements provided it is 
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found to be low. Serum folate can also be measured or, alternatively, it may be appropriate to 
assume that SIBO is present and treat accordingly. 
Treatment 
There is no firm data to suggest that early treatment of dogs heading towards EPI (those with 
biopsy-proven lymphocytic pancreatic infiltration) using immunosuppressant therapy provide any 
benefit. 
Enzyme replacement therapy is indicated for EPI.  Various enzyme extracts are commercially 
available.  Powdered, non-enteric-coated supplements are recommended (~ 1 teaspoon added to 
each meal).  Enteric-coated forms are reported not to work so well, because they are retained in the 
stomach. Alternatively, in some countries, it is legal to purchase and use raw pancreas to treat this 
disease. 
H2 receptor antagonists can be used if response to enzyme supplementation is poor.  These antacid 
drugs may increase the amount of enzyme supplement that survives passage through the stomach.  
Preincubation of soft food with enzyme supplements has been advocated, but whether it provide 
any real benefit is uncertain. 
A highly digestible, low fibre, moderate fat food may be helpful in some patients but many animals 
do not need to be fed a special diet.  Fat restriction may be advisable because enzyme 
supplementation is insufficient to match normal lipase production. 
Antibiotic therapy (e.g., tetracycline, metronidazole) can be used in selected animals in which SIBO 
is demonstrated or strongly suspected.  If response to enzyme supplementation alone is satisfactory, 
they should not be needed. 
In some dogs with EPI, cobalamin deficiency can be demonstrated.  Enzyme supplementation 
should not be expected to resolve this problem.  Parenteral supplementation (250-500µg/dose) and 
monitoring of serum levels may be necessary. 
Prognosis 
There is usually a prompt response to therapy with improved faecal consistency, decreased 
polyphagia and weight gain.  Treatment must be continued indefinitely and can be expensive some 
clients. Over the long-term, it has been reported that approximately 50% of dogs can be rendered 
essentially normal.  20% have are relatively poor response. Euthanasia is carried out in about 20% 
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of cases during the first year after the diagnosis is made.  The cost of treatment and/or poor 
response to treatment are thought to be responsible. 
 
  
Other pancreatic diseases of dogs and cats 
There are numerous other kinds of pancreatic disease that are relatively uncommon.  These 
include:- 
• pancreatic pseudocyst; 
• pancreatic abscess; 
• exocrine pancreatic neoplasia; 
• pancreatic parasites; and 
• nodular hyperplasia. 
 
